Total Payments
$1.5M
2024 Payments
$224,929
Companies
49
Transactions
2,652
Medicare Patients
1,266
Medicare Billing
$83,644
Payment Breakdown by Category
Other$1.0M (67.8%)
Travel$235,869 (15.4%)
Consulting$181,439 (11.9%)
Food & Beverage$53,032 (3.5%)
Research$20,766 (1.4%)
Education$1,244 (0.1%)
Gifts$118.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $862,659 | 447 | 56.4% |
| Travel and Lodging | $235,869 | 724 | 15.4% |
| Consulting Fee | $181,439 | 62 | 11.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $141,145 | 57 | 9.2% |
| Food and Beverage | $53,032 | 1,290 | 3.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $29,500 | 9 | 1.9% |
| Unspecified | $20,766 | 44 | 1.4% |
| Honoraria | $2,850 | 2 | 0.2% |
| Education | $1,244 | 15 | 0.1% |
| Gift | $118.80 | 2 | 0.0% |
Payments by Type
General
$1.5M
2,608 transactions
Research
$20,766
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $650,985 | 739 | $0 (2024) |
| Dexcom, Inc. | $175,308 | 258 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $125,618 | 175 | $0 (2021) |
| Lilly USA, LLC | $99,887 | 219 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $94,979 | 79 | $0 (2024) |
| Valeritas, Inc. | $86,276 | 112 | $0 (2019) |
| Insulet Corporation | $72,812 | 214 | $0 (2024) |
| Abbott Laboratories | $58,511 | 120 | $0 (2024) |
| Mannkind Corporation | $32,694 | 159 | $0 (2024) |
| Medtronic, Inc. | $23,709 | 57 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $224,929 | 390 | Lilly USA, LLC ($71,959) |
| 2023 | $167,923 | 321 | Dexcom, Inc. ($80,551) |
| 2022 | $122,306 | 285 | Novo Nordisk Inc ($88,920) |
| 2021 | $131,164 | 266 | Novo Nordisk Inc ($91,515) |
| 2020 | $78,032 | 181 | Novo Nordisk Inc ($56,086) |
| 2019 | $344,575 | 443 | Novo Nordisk Inc ($127,249) |
| 2018 | $213,479 | 374 | Novo Nordisk Inc ($104,258) |
| 2017 | $246,215 | 392 | Novo Nordisk Inc ($119,262) |
All Payment Transactions
2,652 individual payment records from CMS Open Payments — Page 1 of 107
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | In-kind items and services | $583.63 | General |
| Category: Endocrinology | ||||||
| 12/19/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,447.00 | General |
| Category: Endocrinology | ||||||
| 12/19/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Food and Beverage | In-kind items and services | $30.67 | General |
| Category: Endocrinology | ||||||
| 12/19/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: Endocrinology | ||||||
| 12/18/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $9.17 | General |
| Category: Endocrinology | ||||||
| 12/17/2024 | Insulet Corporation | Omnipod (Device) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $350.00 | General |
| Category: Insulin Pump | ||||||
| 12/17/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | Cash or cash equivalent | $118.75 | General |
| Category: Endocrinology | ||||||
| 12/03/2024 | Insulet Corporation | Omnipod (Device) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Insulin Pump | ||||||
| 12/03/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $128.49 | General |
| Category: Automated insulin delivery system | ||||||
| 12/03/2024 | Insulet Corporation | Omnipod (Device) | Travel and Lodging | Cash or cash equivalent | $26.80 | General |
| Category: Insulin Pump | ||||||
| 12/03/2024 | Insulet Corporation | Omnipod (Device) | Travel and Lodging | Cash or cash equivalent | $12.00 | General |
| Category: Insulin Pump | ||||||
| 11/29/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $143.94 | General |
| Category: Diabetes Care | ||||||
| 11/27/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $7.17 | General |
| Category: Endocrinology | ||||||
| 11/26/2024 | Insulet Corporation | Omnipod (Device) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,150.00 | General |
| Category: Insulin Pump | ||||||
| 11/26/2024 | Insulet Corporation | Omnipod (Device) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Insulin Pump | ||||||
| 11/26/2024 | Insulet Corporation | Omnipod (Device) | Travel and Lodging | Cash or cash equivalent | $32.00 | General |
| Category: Insulin Pump | ||||||
| 11/26/2024 | Insulet Corporation | Omnipod (Device) | Travel and Lodging | Cash or cash equivalent | $32.00 | General |
| Category: Insulin Pump | ||||||
| 11/26/2024 | Insulet Corporation | Omnipod (Device) | Travel and Lodging | Cash or cash equivalent | $17.96 | General |
| Category: Insulin Pump | ||||||
| 11/22/2024 | Novo Nordisk Inc | Victoza (Drug) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: Diabetes | ||||||
| 11/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | In-kind items and services | $776.88 | General |
| Category: Endocrinology | ||||||
| 11/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | In-kind items and services | $415.91 | General |
| Category: Endocrinology | ||||||
| 11/20/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,434.38 | General |
| Category: Diabetes Care | ||||||
| 11/20/2024 | Sequel Med Tech, LLC | — | Food and Beverage | In-kind items and services | $122.03 | General |
| 11/20/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Travel and Lodging | In-kind items and services | $32.00 | General |
| Category: Diabetes Care | ||||||
| 11/20/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $15.82 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION | Eli Lilly and Company | $6,984 | 2 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND COMPARISON OF LY900014 AND FIASP, BOTH IN COMBINATION WITH BASAL INSULIN IN ADULTS WITH TYPE 1 DIABETES PROTO COMPARE | Eli Lilly and Company | $3,000 | 1 |
| Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM;,Efficacy and Safety o | SANOFI-AVENTIS U.S. LLC | $2,693 | 1 |
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,563 | 11 |
| iGlarLixi Ethnicity ADA ; Relationship Of Ethnicity To Clinical Outcomes In iGlarLixi Treated Patients With Type 2 Diabetes | SANOFI-AVENTIS U.S. LLC | $1,504 | 1 |
| Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine | SANOFI-AVENTIS U.S. LLC | $1,235 | 11 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua?100/33 Versus Lantus? in Ethnically/Racially Di | SANOFI US SERVICES INC. | $1,173 | 11 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $1,008 | 1 |
| A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to i | SANOFI-AVENTIS U.S. LLC | $635.80 | 1 |
| A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to I | SANOFI-AVENTIS U.S. LLC | $413.80 | 2 |
| AE and Safety review; A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide | SANOFI-AVENTIS U.S. LLC | $411.40 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $145.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 386 | 829 | $72,269 | $24,172 |
| 2022 | 13 | 373 | 753 | $68,213 | $23,630 |
| 2021 | 13 | 354 | 740 | $61,402 | $23,281 |
| 2020 | 4 | 153 | 380 | $26,412 | $12,561 |
Total Patients
1,266
Total Services
2,702
Medicare Billing
$83,644
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 187 | $49,390 | $16,587 | 33.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 51 | 147 | $13,230 | $3,629 | 27.4% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 64 | 157 | $4,182 | $1,486 | 35.5% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 62 | 173 | $1,135 | $552.45 | 48.7% |
| 82306 | Vitamin d-3 level | Office | 2023 | 15 | 17 | $1,118 | $493.17 | 44.1% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 20 | 23 | $763.60 | $378.58 | 49.6% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 19 | 21 | $630.00 | $275.52 | 43.7% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 20 | 23 | $460.92 | $203.32 | 44.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 16 | 19 | $570.00 | $196.65 | 34.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 17 | 19 | $364.42 | $144.59 | 39.7% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 14 | 16 | $184.96 | $90.56 | 49.0% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 14 | 16 | $184.00 | $81.28 | 44.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 11 | 11 | $55.00 | $53.90 | 98.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 72 | 190 | $50,183 | $16,973 | 33.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 45 | 118 | $9,365 | $3,094 | 33.0% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 65 | 148 | $3,943 | $1,420 | 36.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 62 | 159 | $1,043 | $515.00 | 49.4% |
| 82306 | Vitamin d-3 level | Office | 2022 | 16 | 17 | $1,118 | $499.36 | 44.7% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2022 | 16 | 17 | $564.40 | $283.39 | 50.2% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 16 | 17 | $510.00 | $225.75 | 44.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 15 | 16 | $480.00 | $167.59 | 34.9% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2022 | 16 | 17 | $340.68 | $152.17 | 44.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 15 | 16 | $306.88 | $123.28 | 40.2% |
| 82043 | Urine microalbumin (protein) level | Office | 2022 | 12 | 13 | $150.28 | $74.60 | 49.6% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2022 | 12 | 13 | $149.50 | $66.89 | 44.7% |
About Dr. Pablo Mora, MD
Dr. Pablo Mora, MD is a Internal Medicine healthcare provider based in Plano, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1306836168.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pablo Mora, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $224,929 received in 2024. These payments were reported across 2,652 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($862,659).
As a Medicare-enrolled provider, Mora has provided services to 1,266 Medicare beneficiaries, totaling 2,702 services with total Medicare billing of $83,644. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Plano, TX
- Active Since 10/24/2005
- Last Updated 12/29/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1306836168
Products in Payments
- Ozempic (Drug) $241,360
- Tresiba (Drug) $124,706
- DEXCOM G7 GSS (161) (Medical Supply) $115,883
- STEGLATRO (Drug) $100,268
- V-GO (Device) $86,276
- Victoza (Drug) $76,267
- Omnipod (Device) $72,812
- FREESTYLE LIBRE 3 (Device) $57,882
- SOLIQUA 100/33 (Drug) $55,753
- RYBELSUS (Drug) $51,589
- Rybelsus (Drug) $40,706
- AFREZZA (Drug) $32,694
- Dexcom G6 Transmitter (Medical Supply) $27,316
- Xultophy 100/3.6 (Drug) $26,794
- SOLIQUA (Drug) $26,457
- LYUMJEV (Drug) $24,903
- INVOKANA (Drug) $22,392
- DEXCOM G6 TRANSMITTER (Device) $22,197
- MINIMED 780G (Device) $20,450
- DC ACCU-CHEK Diabetes Management Solutions, Cables, Software, Kits and Accessories (Device) $19,714
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Plano
Sameh Sayfo
Internal Medicine — Payments: $750,028
Internal Medicine $750,028
Dr. Tanvir Ahmad, Md, MD
Internal Medicine — Payments: $63,903
Internal Medicine $63,903
Ali Mithani, M.d, M.D
Internal Medicine — Payments: $63,791
Internal Medicine $63,791
Terilyn Scott-Winful, M.d, M.D
Internal Medicine — Payments: $53,016
Internal Medicine $53,016
Dr. Brian Schwartz, M.d, M.D
Internal Medicine — Payments: $37,610
Internal Medicine $37,610
Haider Nazeer, M.d, M.D
Internal Medicine — Payments: $36,066
Internal Medicine $36,066